Share This Article:

Anti-Inflammatory Efficacy of Product Containing “Skin Calm Complex” in Vitro Reconstructed Epidermis

Full-Text HTML XML Download Download as PDF (Size:2942KB) PP. 309-315
DOI: 10.4236/jcdsa.2014.45040    1,923 Downloads   2,336 Views  

ABSTRACT

Atopic dermatitis is classified as a chronic inflammatory skin disease, which is characterized by alterations in barrier function and immune system of the skin. In a previous study, the efficacy of REPAVAR ATOPIC SKIN BODY CREAM EXTREME (a product containing “SKIN CALM COMPLEX”) on the epidermal barrier structure was demonstrated. However, the product has also been formulated to improve inflammation and itching. The aim of this study is to analyze product effectiveness on skin inflammation and itching which is associated with atopic dermatitis, by quantification of IL-1α and IL-8 interleukins secreted by human keratinocytes from reconstructed epidermis by ELISA assay. Mature (aged 17 days) sample tissues were treated with pro-inflammatory agents (PBS 1X and LPS) and with the product containing synergistic mix from plants extracts and Dihydroavenanthramide D, among other ingredients (“SKIN CALM COMPLEX”) for 24 hours. Measuring the amounts of interleukins by ELISA assay showed 1) decreased levels of IL-1α and 2) no differences about IL-8 secretion. Product REPAVAR ATOPIC SKIN BODY CREAM EXTREME has an anti-inflammatory effect on the release of pro-inflammatory cytokines, becoming an effective preventive agent on inflammation and itching due to maintenance and improvement of the keratinocyte epidermal structure.

Cite this paper

Yzaguirre, M. , Bacchini, G. , Luna, E. and Vila-Martínez, E. (2014) Anti-Inflammatory Efficacy of Product Containing “Skin Calm Complex” in Vitro Reconstructed Epidermis. Journal of Cosmetics, Dermatological Sciences and Applications, 4, 309-315. doi: 10.4236/jcdsa.2014.45040.

References

[1] Boguniewicz, M. and Leung, D.Y. (2011) Atopic Dermatitis: A Disease of Altered Skin Barrier and Immune Dysregulation. Immunological Reviews, 242, 233-246.
http://dx.doi.org/10.1111/j.1600-065X.2011.01027.x
[2] Kasraie, S. and Werfel, T. (2013) Role of Macrophages in the Pathogenesis of Atopic Dermatitis. Mediators of Inflammation, 2013, 1-15. http://dx.doi.org/10.1155/2013/942375
[3] Segre, J.A. (2006) Epidermal Barrier Formation and Recovery in Skin Disorders. The Journal of Clinical Investigation, 116, 1150-1158. http://dx.doi.org/10.1172/JCI28521
[4] Jensen, L.E. (2010) Targeting the IL-1 Family Members in Skin Inflammation. Current Opinion in Investigational Drugs, 11, 1211-1220.
[5] Engelhart, K., El Hindi, T., Biesalski, H.K. and Pfitzner, I. (2005) In Vitro Reproduction of Clinical Hallmarks of Eczematous Dermatitis in Organotypic Skin Models. Archives of Dermatological Research, 297, 1-9.http://dx.doi.org/10.1007/s00403-005-0575-7
[6] Tivoli, Y.A. and Rubenstein, R.M. (2009) Pruritus: An Updated Look at an Old Problem. Journal of Clinical and Aesthetic Dermatology, 2, 30-36.
[7] Steinhoff, M., Bienenstock, J., Schmelz, M., Maurer, M., Wei, E. and Bíró, T. (2006) Neurophysiological, Neuroimmunological, and Neuroendocrine Basis of Pruritus. Journal of Investigative Dermatology, 126, 1705-1718.http://dx.doi.org/10.1038/sj.jid.5700231
[8] Pastar, Z., Lipozencic, J. and Ljubojevic, S. (2005) Etiopathogenesis of Atopic Dermatitis—An Overview. Acta Dermatovenerologica Croatica, 13, 54-62.
[9] Polo, N. (2003) Dermatitis atópica. JANO, 1.475, 42-44.
[10] Novak, N. and Leung, D.Y. (2011) Advances in Atopic Dermatitis. Current Opinion in Immunology, 23, 778-783.http://dx.doi.org/10.1016/j.coi.2011.09.007
[11] Elias, P.M. (2010) Therapeutic Implications of a Barrier-Based Pathogenesis of Atopic Dermatitis. Annals of Dermatology, 22, 245-254. http://dx.doi.org/10.5021/ad.2010.22.3.245
[12] Ballona, R. and Ballona, C. (2004) Dermatitis atópica. Folia Dermatológica Peruana, 15, 40-48.
[13] Theoharides, T.C., Alysandratos, K.D., Angelidou, A., Delivanis, D.A., Sismanopoulos, N., Zhang, B., Asadi, S., Vasiadi, M., Weng, Z., Miniati, A. and Kalogeromitros, D. (2012) Mast Cells and Inflammation. Biochimica et Biophysica Acta, 1822, 21-33.
[14] Elias, P.M. and Schmuth, M. (2009) Abnormal Skin Barrier in the Etiopathogenesis of Atopic Dermatitis. Current Allergy and Asthma Reports, 9, 265-272.
http://dx.doi.org/10.1007/s11882-009-0037-y
[15] Komine, M. (2009) Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Keratinocytes in Atopic Dermatitis—Their Pathogenic Involvement. Journal of Pharmacological Sciences, 110, 260-264. http://dx.doi.org/10.1254/jphs.09R06FM
[16] Klein, P.A. and Clark, R.A. (1999) An Evidence-Based Review of the Efficacy of Antihistamines in Relieving Pruritus in Atopic Dermatitis. JAMA Dermatology, 135, 1522-1525.
http://dx.doi.org/10.1001/archderm.135.12.1522
[17] Brandt, E.B. and Sivaprasad, U. (2011) Th2 Cytokines and Atopic Dermatitis. Journal of Clinical & Cellular Immunology, 2, 110-123. http://dx.doi.org/10.4172/2155-9899.1000110
[18] Sonkoly, E., Muller, A., Lauerma, A.I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.C., Meller, S., Rieker, J., Steinhoff, M., Hoffmann, T.K., Ruzicka, T., Zlotnik, A. and Homey, B. (2006) IL-31: A New Link between T Cells and Pruritus in Atopic Skin Inflammation. Journal of Allergy and Clinical Immunology, 117, 411-417. http://dx.doi.org/10.1016/j.jaci.2005.10.033
[19] http://www.skinethic.com/RHE.asp
[20] Merlin, J.L., Azzi, S., Lignon, D., Ramacci, C., Zeghari, N. and Guillemin, F. (1992) MTT Assays Allow Quick and Reliable Measurement of the Response of Human Tumour Cells to Photodynamic Therapy. European Journal of Cancer, 28, 1452-1458. http://dx.doi.org/10.1016/0959-8049(92)90542-A
[21] Matabuena-de Yzaguirre, M., Bacchini, G., Vila-Martínez, E. and Juarranz, A. (2014) Product Containing “Skin Calm Complex” Improves Barrier Effect in Vitro. Journal of Cosmetics, Dermatological Sciences and Applications, 4, 234-243. http://dx.doi.org/10.4236/jcdsa.2014.44032
[22] Venge, P. (1993) Eosinophil and Neutrophil Granulocytes. Allergy, 48, 39-47.
http://dx.doi.org/10.1111/j.1398-9995.1993.tb04697.x
[23] Hong, J., Buddenkotte, J., Berger, T.G. and Steinhoff, M. (2011) Management of Itch in Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 30, 71-86.
http://dx.doi.org/10.1016/j.sder.2011.05.002
[24] Lee, J., Jung, E., Park, B., Jung, K., Park, J., Kim, K., Kim, K.H. and Park, D. (2005) Evaluation of the Anti-Inflammatory and Atopic Dermatitis-Mitigating Effects of BSASM, a Multicompound Preparation. Journal of Ethnopharmacology, 96, 211-219. http://dx.doi.org/10.1016/j.jep.2004.09.012
[25] Sur, R., Nigam, A., Grote, D., Liebel, F. and Southall, M.D. (2008) Avenanthramides, Polyphenols from Oats, Exhibit Anti-Inflammatory and Anti-Itch Activity. Archives of Dermatological Research, 300, 569-574. http://dx.doi.org/10.1007/s00403-008-0858-x
[26] Albanesi, C., Scarponi, C., Giustizieri, M.L. and Girolomoni, G. (2005) Keratinocytes in Inflammatory Skin Diseases. Current Drug Target-Inflammation & Allergy, 4, 329-334.
http://dx.doi.org/10.2174/1568010054022033
[27] Uchiyama, N., Yamamoto, A., Kameda, K., Yamaguchi, H. and Ito, M. (2000) The Activity of Fatty Acid Synthase of Epidermal Keratinocytes Is Regulated in the Lower Stratum Spinousum and the Stratum Basale by Local Inflammation Rather than by Circulating Hormones. Journal of Dermatological Science, 24, 134-141. http://dx.doi.org/10.1016/S0923-1811(00)00088-8

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.